FOSTER CITY, CA--(Marketwired - February 10, 2014) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Charles Meng as General Counsel and Vice President of Compliance effective February 9, 2014. Mr. Meng has more than 20 years of experience in compliance and legal affairs spanning multinational companies in diverse industries, including pharmaceuticals, high technology and electronics, as well as in academia and government service. Mr. Meng will report to Friedhelm Blobel, Ph.D., Chief Executive Officer, and will be based in SciClone's Shanghai headquarters.
"Charles is a proficient legal and compliance professional with an excellent track record of ensuring that companies operate to the strictest standards of quality, integrity and ethical behavior throughout their organizations," said Dr. Blobel. "Charles' international perspective, understanding of complex regulatory requirements in both the US and China markets and expertise in managing large and diverse teams will be especially valuable to SciClone as we continue to pursue commercial growth and expansion. I am particularly pleased with the continuous strengthening of SciClone's executive management team in the US and China over the last several quarters, and believe that Charles will be a great addition to this high quality group."
Mr. Meng has practiced law and directed compliance programs in both the US and China. He joins SciClone from Novartis Group, Beijing, where he was General Legal Counsel and Chief Compliance Officer for the pharmaceutical division, and also had responsibility for legal and compliance affairs of other divisions or business units of Novartis China, such as the animal health and vaccine divisions, as well as R&D. Prior to Novartis, Mr. Meng served as Chief Legal Officer of China Bluestar in Beijing, a state-owned chemical company. Previously, he held the position of Legal Director, Greater China Region with AMD (China) Ltd., where he oversaw legal issues, compliance, contracts and supply chain management. Earlier in his career he held various positions in legal affairs, including with Motorola (China) Electronics Ltd., Electra Air Conditioning (Shenzhen) Co., Ltd., Allen & Overy, City University of Hong Kong, City Attorneys' Office (US) and the Ministry of Foreign Affairs in Beijing. Mr. Meng earned his LL.B. from Foreign Affairs College in Beijing, his LL.M from the Faculty of Law, Edinburgh University, Scotland, UK, and his J.D. from the College of Law, Ohio State University.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risk and uncertainties relating to: the course, cost and outcome of regulatory matters, including future pricing decisions by authorities in China; the on-going regulatory investigations; the Company's ability to execute on its goals in China and on its objectives for revenue in fiscal 2014; the challenges presented by integrating an acquired business into existing operations; the effect of management changes and turnover in its China operations; the dependence of our current and future revenue and prospects on third-party license, promotion or distribution agreements including the need to renew such agreements or end arrangements that the Company does not believe are beneficial; operating an international business; the clinical trial process, including the regulatory approval and the process of initiating trials at, and enrolling patients at, clinical sites; and the effect of changes in its practices and policies related to the Company's compliance programs. SciClone cannot predict the timing or outcome of the ongoing SEC and DOJ investigations, or of the level of its efforts required to cooperate with those investigations, however the Company has incurred substantial expenses in connection with the investigations and related litigation and expects to incur substantial additional expense and the investigations could result in fines and further changes in its internal control or other remediation measures that could adversely affect its financial results. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
Wilson W. Cheung
Chief Financial Officer